106 related articles for article (PubMed ID: 16794485)
1. Carvedilol-induced antagonism of angiotensin II: a matter of alpha1-adrenoceptor blockade.
Batenburg WW; van Esch JH; Garrelds IM; Jorde U; Lamers JM; Dekkers DH; Walther T; Kellett E; Milligan G; van Kats JP; Danser AH
J Hypertens; 2006 Jul; 24(7):1355-63. PubMed ID: 16794485
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries.
Batenburg WW; Garrelds IM; Bernasconi CC; Juillerat-Jeanneret L; van Kats JP; Saxena PR; Danser AH
Circulation; 2004 May; 109(19):2296-301. PubMed ID: 15117835
[TBL] [Abstract][Full Text] [Related]
3. The effect of losartan and carvedilol on vasopressor responses to adrenergic agonists and angiotensin II in the systemic circulation of Sprague Dawley rats.
Abdulla MH; Sattar MA; Abdullah NA; Khan MA; Anand Swarup KR; Johns EJ
Auton Autacoid Pharmacol; 2011; 31(1-2):13-20. PubMed ID: 21166975
[TBL] [Abstract][Full Text] [Related]
4. Carvedilol blockade of rat myocardial alpha1-adrenoceptors.
Qvigstad E; Osnes JB; Sandnes D; Schiander I; Bøkenes J; Sjaastad I; Skomedal T
Eur J Pharmacol; 2003 Nov; 481(1):83-9. PubMed ID: 14637179
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction.
Yu J; Zhao J; Liu W; Ge Z; Du Y
Heart Vessels; 2011 Nov; 26(6):646-53. PubMed ID: 21229253
[TBL] [Abstract][Full Text] [Related]
6. Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization.
Al-Hesayen A; Azevedo ER; Floras JS; Hollingshead S; Lopaschuk GD; Parker JD
Eur J Heart Fail; 2005 Jun; 7(4):618-23. PubMed ID: 15921803
[TBL] [Abstract][Full Text] [Related]
7. Carvedilol blocks beta2- more than beta1-adrenoceptors in human heart.
Molenaar P; Christ T; Ravens U; Kaumann A
Cardiovasc Res; 2006 Jan; 69(1):128-39. PubMed ID: 16225854
[TBL] [Abstract][Full Text] [Related]
8. Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
Hanada K; Asari K; Saito M; Kawana J; Mita M; Ogata H
Eur J Pharmacol; 2008 Jul; 589(1-3):194-200. PubMed ID: 18534575
[TBL] [Abstract][Full Text] [Related]
9. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study.
Jacob S; Rett K; Wicklmayr M; Agrawal B; Augustin HJ; Dietze GJ
J Hypertens; 1996 Apr; 14(4):489-94. PubMed ID: 8761899
[TBL] [Abstract][Full Text] [Related]
10. Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol.
Kveiborg B; Christiansen B; Major-Petersen A; Torp-Pedersen C
Am J Cardiovasc Drugs; 2006; 6(4):209-17. PubMed ID: 16913822
[TBL] [Abstract][Full Text] [Related]
11. Influence of sympathetic and AT-receptor blockade on angiotensin II and adrenergic agonist-induced renal vasoconstrictions in spontaneously hypertensive rats.
Abdulla MH; Sattar MA; Khan MA; Abdullah NA; Johns EJ
Acta Physiol (Oxf); 2009 Mar; 195(3):397-404. PubMed ID: 19183357
[TBL] [Abstract][Full Text] [Related]
12. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of carvedilol and metoprolol on isoprenaline-induced changes in beta-adrenoceptor density and systolic function in rat cardiac myocytes.
Flesch M; Ettelbrück S; Rosenkranz S; Maack C; Cremers B; Schlüter KD; Zolk O; Böhm M
Cardiovasc Res; 2001 Feb; 49(2):371-80. PubMed ID: 11164847
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure.
Qvigstad E; Sjaastad I; Bøkenes J; Schiander I; Solberg L; Sejersted OM; Osnes JB; Skomedal T
Eur J Pharmacol; 2005 May; 516(1):51-9. PubMed ID: 15916756
[TBL] [Abstract][Full Text] [Related]
15. Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction.
Li YC; Ge LS; Yang PL; Tang JF; Lin JF; Chen P; Guan XQ
Eur J Pharmacol; 2010 Aug; 640(1-3):112-6. PubMed ID: 20457150
[TBL] [Abstract][Full Text] [Related]
16. Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors.
Koshimizu TA; Tsujimoto G; Hirasawa A; Kitagawa Y; Tanoue A
Cardiovasc Res; 2004 Sep; 63(4):662-72. PubMed ID: 15306222
[TBL] [Abstract][Full Text] [Related]
17. Anti-thrombotic effects of nebivolol and carvedilol: Involvement of β2 receptors and COX-2/PGI2 pathways.
Kozlovski VI; Lomnicka M; Bartus M; Sternak M; Chlopicki S
Pharmacol Rep; 2015 Oct; 67(5):1041-7. PubMed ID: 26398401
[TBL] [Abstract][Full Text] [Related]
18. Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304).
Song G; Hennessy M; Zhao YL; Li Q; Han WD; Qi Y; Zhao WN; Silke B; Barry M; Doyle R; Spiers JP
Pharmacol Res; 2006 Jul; 54(1):57-64. PubMed ID: 16574429
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes.
Wang R; Miura T; Harada N; Kametani R; Shibuya M; Fukagawa Y; Kawamura S; Ikeda Y; Hara M; Matsuzaki M
J Pharmacol Exp Ther; 2006 Jul; 318(1):45-52. PubMed ID: 16611853
[TBL] [Abstract][Full Text] [Related]
20. Effects of adrenoceptor blocking drugs on cardiovascular responsiveness to passive orthostasis: a placebo-controlled double-blind study.
Nieminen T; Ylitalo R; Kööbi T; Ylitalo P; Kähönen M
Arzneimittelforschung; 2005; 55(4):205-11. PubMed ID: 15901043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
